Plain-English translation of NCT06707493 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a medication called can help prevent acute myeloid leukemia (AML) from returning after you receive a stem cell transplant. Half of the participants will receive the medication by mouth once daily, and half will receive a placebo (a pill with no active ingredient). The goal is to see if this treatment can keep the cancer from coming back.
Acute myeloid leukemia can sometimes return even after a successful stem cell transplant, which is why doctors are looking for ways to prevent this. This medication has already been approved for treating AML in other situations, and researchers want to know if it can work as a preventive treatment after transplant.
You likely qualify if…
You likely don't qualify if…
After you have your stem cell transplant and your body has recovered for 45 to 90 days, you will start taking either the medication or a placebo once daily by mouth in 28-day cycles. You will continue this for up to 24 months, with regular study visits and blood tests to check how you are doing. After the 24-month treatment period ends, you will be followed for another year to track your long-term health.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States